Publications
September 8, 2014
Use of genetic technologies to compare medicines
In order to ensure that patients receive the safest and most effective medicines possible, it is often necessary to compare medicines and assess the extent to which they are similar…
Journal: Clinical Genetics
May 22, 2014
BIOMARKERS FOR PREDICTING CLINICAL RESPONSE OF CANCER PATIENTS TO TREATMENT WITH IMMUNOTHERAPEUTIC AGENT
Provided herein are prognostic and diagnostic methods for predicting likelihood of clinical response of a subject having cancer to treatment with an immunotherapeutic agent. Also provided herein are methods for…
January 8, 2014
Comparing the Biological Impact of Glatiramer Acetate with the Biological Impact of a Generic
For decades, policies regarding generic medicines have sought to provide patients with economical access to safe and effective drugs, while encouraging the development of new therapies. This balance is becoming…
Journal: PLoS One
March 26, 2013
Defining the Transcriptional and Cellular Landscape of Type 1 Diabetes in the NOD Mouse
Our ability to successfully intervene in disease processes is dependent on definitive diagnosis. In the case of autoimmune disease, this is particularly challenging because progression of disease is lengthy and…
January 2, 2012
Maximizing the efficacy of angiogenesis inhibitors
The article “Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study” by de Groot et al1 was published in Journal of Clinical Oncology….
December 5, 2011
IL-6 and ovarian cancer–letter
Clinical Cancer Research recently published an important study by Coward and colleagues (1) examining interleukin-6 as a target in ovarian cancer and last year published an investigation of the same…
June 12, 2009
Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology
Supported by the Office of International Affairs, National Cancer Institute (NCI), the “US-Japan Workshop on Immunological Biomarkers in Oncology” was held in March 2009. The workshop was related to a…
December 2, 2008
A systematic approach to biomarker discovery; preamble to “the iSBTc-FDA taskforce on immunotherapy biomarkers”
The International Society for the Biological Therapy of Cancer (iSBTc) has initiated in collaboration with the United States Food and Drug Administration (FDA) a programmatic look at innovative avenues for…
Page 9 of 9
